260 related articles for article (PubMed ID: 20604734)
21. Effectiveness of a fenofibrate 145-mg nanoparticle tablet formulation compared with the standard 160-mg tablet in patients with coronary heart disease and dyslipidemia.
Maciejewski S; Hilleman D
Pharmacotherapy; 2008 May; 28(5):570-5. PubMed ID: 18447655
[TBL] [Abstract][Full Text] [Related]
22. Summaries for patients. Response to cholesterol-lowering drugs in patients with and without HIV infection.
Ann Intern Med; 2009 Mar; 150(5):I38. PubMed ID: 19258553
[No Abstract] [Full Text] [Related]
23. The effect of fenofibrate on HDL cholesterol and HDL particle concentration in postmenopausal women on tibolone therapy.
Stuckey BG; Barrett PH; Wagner JM; Hampton RA; Chan DC; Brown SJ; Watts GF
Clin Endocrinol (Oxf); 2010 Oct; 73(4):497-501. PubMed ID: 20560981
[TBL] [Abstract][Full Text] [Related]
24. Predicted coronary heart disease risk in croatian HIV infected patients treated with combination antiretroviral therapy.
Turcinov D; Begovac J
Coll Antropol; 2011 Mar; 35(1):115-21. PubMed ID: 21667536
[TBL] [Abstract][Full Text] [Related]
25. Effect of fenofibrate on Chlamydia pneumoniae antibody levels in patients with coronary artery disease.
Mark L; Katona A; Marki-Zay J
Am J Cardiol; 2002 Jan; 89(1):111. PubMed ID: 11779542
[No Abstract] [Full Text] [Related]
26. Antiretroviral therapy in HIV-positive men is associated with increased apolipoprotein CIII in triglyceride-rich lipoproteins.
Rimland D; Guest JL; Hernández I; Del Rio C; Le NA; Brown WV
HIV Med; 2005 Sep; 6(5):326-33. PubMed ID: 16156880
[TBL] [Abstract][Full Text] [Related]
27. Combination of niacin and fenofibrate with lifestyle changes improves dyslipidemia and hypoadiponectinemia in HIV patients on antiretroviral therapy: results of "heart positive," a randomized, controlled trial.
Balasubramanyam A; Coraza I; Smith EO; Scott LW; Patel P; Iyer D; Taylor AA; Giordano TP; Sekhar RV; Clark P; Cuevas-Sanchez E; Kamble S; Ballantyne CM; Pownall HJ
J Clin Endocrinol Metab; 2011 Jul; 96(7):2236-47. PubMed ID: 21565796
[TBL] [Abstract][Full Text] [Related]
28. Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study.
Friis-Møller N; Weber R; Reiss P; Thiébaut R; Kirk O; d'Arminio Monforte A; Pradier C; Morfeldt L; Mateu S; Law M; El-Sadr W; De Wit S; Sabin CA; Phillips AN; Lundgren JD;
AIDS; 2003 May; 17(8):1179-93. PubMed ID: 12819520
[TBL] [Abstract][Full Text] [Related]
29. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles?
Fontas E; van Leth F; Sabin CA; Friis-Møller N; Rickenbach M; d'Arminio Monforte A; Kirk O; Dupon M; Morfeldt L; Mateu S; Petoumenos K; El-Sadr W; de Wit S; Lundgren JD; Pradier C; Reiss P;
J Infect Dis; 2004 Mar; 189(6):1056-74. PubMed ID: 14999610
[TBL] [Abstract][Full Text] [Related]
30. Management of dyslipidemia in the elderly population.
Gobal FA; Mehta JL
Ther Adv Cardiovasc Dis; 2010 Dec; 4(6):375-83. PubMed ID: 20965950
[TBL] [Abstract][Full Text] [Related]
31. Evaluation and pharmacologic management of the HIV-infected patient with dyslipidemia.
Hardwicke RL; Lewis ST; Grimes RM
J Assoc Nurses AIDS Care; 2010; 21(5):429-38. PubMed ID: 20303794
[TBL] [Abstract][Full Text] [Related]
32. Evidence on the Protective Role of High-Density Lipoprotein (HDL) in HIV-Infected Individuals.
Calmy A; Montecucco F; James RW
Curr Vasc Pharmacol; 2015; 13(2):167-72. PubMed ID: 24188489
[TBL] [Abstract][Full Text] [Related]
33. Response to newly prescribed lipid-lowering therapy in patients with and without HIV infection.
Silverberg MJ; Leyden W; Hurley L; Go AS; Quesenberry CP; Klein D; Horberg MA
Ann Intern Med; 2009 Mar; 150(5):301-13. PubMed ID: 19258558
[TBL] [Abstract][Full Text] [Related]
34. Treatment of HIV-associated dyslipidemia: a role for omega-3 fatty acids.
Metroka CE; Truong P; Gotto AM
AIDS Read; 2007 Jul; 17(7):362-4, 367-73. PubMed ID: 17672015
[TBL] [Abstract][Full Text] [Related]
35. Management of lipid disorders in patients living with HIV.
Myerson M; Malvestutto C; Aberg JA
J Clin Pharmacol; 2015 Sep; 55(9):957-74. PubMed ID: 25651539
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of fenofibric acid plus statins on multiple lipid parameters and its safety in women with mixed dyslipidemia.
Goldberg AC; Bittner V; Pepine CJ; Kelly MT; Thakker K; Setze CM; Lele A; Sleep DJ
Am J Cardiol; 2011 Mar; 107(6):898-905. PubMed ID: 21247520
[TBL] [Abstract][Full Text] [Related]
37. More clinical lessons from the FIELD study.
Fazio S
Cardiovasc Drugs Ther; 2009 Jun; 23(3):235-41. PubMed ID: 19160032
[TBL] [Abstract][Full Text] [Related]
38. [Effect of antilipemic therapy on patients with diabetes mellitus and obesity].
Ungureanu D; Coman A; Maftei M; Popovici I; Artenie A; Artenie R
Rev Med Chir Soc Med Nat Iasi; 2003; 107(3):551-5. PubMed ID: 14756060
[TBL] [Abstract][Full Text] [Related]
39. Pharmacoepidemiology safety study of fibrate and statin concomitant therapy.
Enger C; Gately R; Ming EE; Niemcryk SJ; Williams L; McAfee AT
Am J Cardiol; 2010 Dec; 106(11):1594-601. PubMed ID: 21094360
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.
Davidson MH; Rooney MW; Drucker J; Eugene Griffin H; Oosman S; Beckert M;
Clin Ther; 2009 Dec; 31(12):2824-38. PubMed ID: 20110022
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
